Skip to main content

Table 10 Differences in the approach to a third line treatment of CSU in physicians who do and do not follow the guidelines

From: Management of chronic spontaneous urticaria: a worldwide perspective

Treatment

Compared groups

n

% (n) of physicians, who follow the guidelines

% (n) of physicians, who don’t follow the guidelines

X2

p

First-generation H1-antihistamines

Administer

93

7.7 (80)

14.8 (13)

5.345

0.021

No

1033

92.3 (958)

85.2 (75)

Second-generation H1-antihistamines at standard dose

Administer

78

6.9 (72)

6.8 (6)

0.002

0.967

No

1048

93.1 (966)

93.2 (82)

Updosed second-generation H1-antihistamines

Administer

283

25.4 (264)

21.6 (19)

0.637

0.425

No

843

74.6 (774)

78.4 (69)

H2-antihistamines (e.g. famotidine or ranitidine)

Administer

206

18.3 (190)

18.2 (16)

0.001

0.977

No

920

81.7 (848)

81.8 (72)

Ciclosporin

Administer

254

23.1 (240)

15.9 (14)

2.416

0.120

No

872

76.9 (798)

84.1 (74)

Omalizumab

Administer

570

51.8 (538)

36.4 (32)

7.764

0.005

No

556

48.2 (500)

63.6 (56)

Montelukast

Administer

319

28.9 (300)

21.6 (19)

2.135

0.144

No

807

71.1 (738)

78.4 (69)

Dapsone

Administer

91

7.8 (81)

11.4 (10)

1.384

0.239

No

1035

92.2 (957)

88.6 (78)

Systemic corticosteroids (for less than 10 days)

Administer

227

20.1 (209)

20.5 (18)

0.005

0.943

No

899

79.9 (829)

79.5 (70)

Systemic corticosteroids (for more than 10 days in a row)

Administer

146

12.7 (132)

15.9 (14)

0.733

0.392

No

980

87.3 (906)

84.1 (74)

Tricyclic antidepressants (e.g. doxepin)

Administer

134

11.7 (121)

14.8 (13)

0.751

0.386

No

992

88.3 (917)

85.2 (75)

  1. Values marked in bold indicate a statistically significant difference (p < 0.05)